Serguei Kozlov,
Leidos Biomedical Research, Inc. Principal Scientist,
Center for Advancer Preclinical Research, NIH
Principal Scientist/PM, CAPR, Leidos Biomedical Research, Inc. Internationally recognized expert in advanced methodologies of generating diverse preclinical murine models (including genetically engineered mouse (GEM) models, GEM-derived syngeneic allograft (GDA) models, patient-derived (PDX) and conventional cell lines-based xenograft models) for studies of the molecular mechanisms of carcinogenesis, tumor immune response, immune surveillance, and inflammation, mechanisms of drug resistance, implication of cancer stem cells, etc.; and to explore such models for preclinical drug development, disease systems analyses and biomarker discovery. Initiated, supervised, and successfully conducted multiple research projects and independent large-scale research and development programs aimed at investigation of molecular mechanisms governing carcinogenesis, biomarker discovery and preclinical drug evaluation in GEM vs. GDA vs. PDX mouse models. Oversee from day one launch and operations of the NCI Center for Advanced Preclinical Research – an innovative preclinical cancer modeling and drug development initiative based on genetically engineered murine models – with senior management responsibilities. Co-authored over 60 scientific papers, book chapters and original works in peer-reviewed journals.
Deciphering Signaling Networks and Mining for Biomarkers in Genetically Engineered Models of Cancer
Thursday, 15 January 2015 at 15:30
Add to Calendar ▼2015-01-15 15:30:002015-01-15 16:30:00Europe/LondonDeciphering Signaling Networks and Mining for Biomarkers in Genetically Engineered Models of CancerPrognostic, Predictive, and POC: Biomarkers from Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
In a quest of improved, more clinically relevant in vivo testing systems mimicking cancer disease, genetically and biologically engineered murine (GEM) models are rapidly gaining reputation of a better predictive platform for discovery of prognostic/diagnostic biomarkers and preclinical drug evaluation. NCI Center for Advanced Preclinical Research (NCI-CAPR) – a broad scope translational initiative tasked with establishing scalable capabilities and best practices in preclinical drug development arena – is developing and managing a portfolio of more than a dozen GEM models faithfully reproducing clinical pictures of pancreatic adenocarcinoma, serous epithelial ovarian carcinoma, non-small cell lung cancer, metastatic melanoma, astrocytoma, and other malignancy types. NCI-CAPR has established rigorous workflows to apply these GEM models in a variety of experimental paradigms aimed at mining systems biology in these animals to pinpoint novel mechanistic aspects of disease progression, or identify informative cancer biomarkers. Such studies are designed to either examine the disease progression from initiation to terminal illness in experimental animals left naïve for therapeutic intervention or treated with a spectrum of oncology compounds, including both standard-of-care and experimental candidate therapeutics. A summary of recent and ongoing experiments will be presented to illustrate the concept of cancer GEM applicability for biomarker data mining and therapeutic discovery.
Add to Calendar ▼2015-01-15 00:00:002015-01-16 00:00:00Europe/LondonPrognostic, Predictive, and POC: Biomarkers from Research to ClinicPrognostic, Predictive, and POC: Biomarkers from Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2015-01-15 15:30:002015-01-15 16:30:00Europe/LondonDeciphering Signaling Networks and Mining for Biomarkers in Genetically Engineered Models of CancerPrognostic, Predictive, and POC: Biomarkers from Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
